/ Deep Track Capital /

Deep Track Capital is one of the largest shareholders of Dynavax Technologies Corporation, with ownership of approximately 14.5% of the Company’s outstanding shares.

Checkbox

Long-term: The senior members of DeepTrack first purchased shares of Dynavax in a financing nearly 15 years ago to support the development of Heplisav.

Checkbox

High conviction: Deep Track has continued to steadily build our position in the Company and purchased shares every quarter from Q4 2022 through Q4 2024.

Checkbox

Industry experts: The firm manages approximately $4 billion on behalf of our investors, which include numerous healthcare organizations and non-profits, and we focus exclusively on investing in the life sciences space.

Checkbox

Informed by experience: Since Deep Track’s inception in 2021, we have directly invested billions of dollars into more than one hundred companies to advance the development of novel therapies.

Checkbox

Uniquely concerned: Deep Track does not typically take active, public roles at companies. Deep Track is not a typical “activist” investor. We are a long-term shareholder that is deeply concerned that the Dynavax Board is leading the Company down a path of value destruction that will have negative consequences for all stakeholders.

As a significant and long-term investor in Dynavax, our interests have always been – and continue to be – directly aligned with those of all shareholders.

/ WE WANT TO HEAR FROM YOU /

For Investors

Innisfree M&A Incorporated
Scott Winter / Gabrielle Wolf
+1 212-750-5833

For Media Inquiries

Longacre Square Partners
deeptrack@longacresquare.com

Subscribe for Updates

Enter your name and email address below to receive important updates

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.